Insulet (PODD) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Insulet (PODD) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Insulet | 10.18 Bn | 9.64 Bn | 562.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.28% |
| Mar 31, 2026 | -10.42% |
| Dec 31, 2025 | 16.10% |
| Sep 30, 2025 | 289.33% |
| Jun 30, 2025 | -36.62% |
| Mar 31, 2025 | -64.75% |
| Dec 31, 2024 | 29.94% |
| Sep 30, 2024 | -58.91% |
| Jun 30, 2024 | 266.21% |
| Mar 31, 2024 | -50.19% |
| Dec 31, 2023 | 99.23% |
| Sep 30, 2023 | 90.11% |
| Jun 30, 2023 | 14.71% |
| Mar 31, 2023 | 40.00% |
| Dec 31, 2022 | 426.92% |
| Sep 30, 2022 | 85.14% |
| Jun 30, 2022 | -225.90% |
| Mar 31, 2022 | -4.79% |
| Dec 31, 2021 | 131.75% |
| Sep 30, 2021 | 150.40% |